DexCom, Inc. (NASDAQ:DXCM) – Equities research analysts at William Blair boosted their Q4 2019 EPS estimates for DexCom in a report issued on Thursday, November 7th. William Blair analyst M. Kaczor now forecasts that the medical device company will post earnings of $0.83 per share for the quarter, up from their previous forecast of $0.71. William Blair also issued estimates for DexCom’s FY2021 earnings at $2.07 EPS.
Several other equities analysts have also recently issued reports on DXCM. Bank of America boosted their target price on shares of DexCom from $162.00 to $185.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Raymond James boosted their target price on shares of DexCom from $172.00 to $189.00 and gave the company an “outperform” rating in a research note on Thursday. Guggenheim upgraded shares of DexCom from a “neutral” rating to a “buy” rating in a research note on Thursday. Canaccord Genuity boosted their target price on shares of DexCom from $185.00 to $195.00 and gave the company a “buy” rating in a research note on Thursday. Finally, ValuEngine cut shares of DexCom from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Five investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. DexCom presently has an average rating of “Buy” and an average target price of $190.67.
Shares of DXCM traded up $3.38 during trading hours on Friday, hitting $198.08. The stock had a trading volume of 2,580,200 shares, compared to its average volume of 1,138,483. The company has a debt-to-equity ratio of 1.56, a quick ratio of 5.64 and a current ratio of 6.05. The firm has a 50-day moving average price of $154.75 and a 200 day moving average price of $145.88. DexCom has a fifty-two week low of $105.05 and a fifty-two week high of $200.80. The firm has a market capitalization of $14.00 billion, a price-to-earnings ratio of 660.27 and a beta of 0.64.
DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Wednesday, November 6th. The medical device company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.20 by $0.45. DexCom had a negative net margin of 13.96% and a positive return on equity of 10.41%. The business had revenue of $396.30 million for the quarter, compared to the consensus estimate of $348.99 million. During the same period in the prior year, the firm earned $0.17 EPS. The business’s revenue for the quarter was up 48.6% on a year-over-year basis.
Several institutional investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its holdings in shares of DexCom by 359.4% during the second quarter. Price T Rowe Associates Inc. MD now owns 5,456,834 shares of the medical device company’s stock worth $817,652,000 after buying an additional 4,268,926 shares in the last quarter. Jennison Associates LLC grew its holdings in shares of DexCom by 211.2% during the second quarter. Jennison Associates LLC now owns 1,391,980 shares of the medical device company’s stock worth $208,574,000 after buying an additional 944,642 shares in the last quarter. Nuveen Asset Management LLC grew its holdings in shares of DexCom by 1,781.3% during the second quarter. Nuveen Asset Management LLC now owns 1,107,735 shares of the medical device company’s stock worth $165,983,000 after buying an additional 1,048,855 shares in the last quarter. Waddell & Reed Financial Inc. grew its holdings in shares of DexCom by 1.8% in the second quarter. Waddell & Reed Financial Inc. now owns 1,056,250 shares of the medical device company’s stock valued at $158,269,000 after purchasing an additional 18,247 shares during the period. Finally, Northern Trust Corp grew its holdings in shares of DexCom by 3.0% in the second quarter. Northern Trust Corp now owns 556,521 shares of the medical device company’s stock valued at $83,388,000 after purchasing an additional 16,056 shares during the period. 96.19% of the stock is owned by institutional investors and hedge funds.
In other DexCom news, SVP Jeffrey Moy sold 4,601 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $149.85, for a total transaction of $689,459.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Heather S. Ace sold 7,243 shares of the company’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $174.80, for a total transaction of $1,266,076.40. The disclosure for this sale can be found here. Insiders have sold 104,014 shares of company stock valued at $16,183,576 over the last 90 days. 1.80% of the stock is currently owned by company insiders.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Further Reading: What moving averages are used to define a golden cross?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.